Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 4 of 23

  1. 413ABM

    BRIGHT MINDS BIOSCIENCES INC.

    MALARIA

    phase 2 other completed

    1 trial

  2. 42 mg transdermal nicotine replacement

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  3. 5 A

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Cessation

    phase 2 other completed

    1 trial

  4. AEF0117

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  5. ATM

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  6. Active Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 2 small molecule on hold

    1 trial

  7. Active rTMS

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 other completed

    1 trial

  8. Adderall-XR and Topiramate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  9. Alprazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Interactions

    phase 2 small molecule active

    1 trial

  10. Aprepitant

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    2 trials

  11. Aripiprazole

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  12. Aripiprazole + Cocaine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Abuse

    phase 2 small molecule completed

    1 trial

  13. Assets Getting To Outcomes

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  14. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  15. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  16. Atomoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Attention Deficit Disorder With Hyperactivity

    phase 2 small molecule completed

    1 trial

  17. B013

    BRIGHT MINDS BIOSCIENCES INC.

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  18. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Prader-Willi Syndrome

    phase 2 small molecule active

    1 trial

  19. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  20. BVRS-GamVac-Combi

    BRIGHT MINDS BIOSCIENCES INC.

    MERS (Middle East Respiratory Syndrome)

    phase 2 small molecule active

    1 trial

  21. BXCL501 (180 micrograms)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  22. BZD discontinuation protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  23. Baclofen

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule completed

    1 trial

  24. Baclofen

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  25. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

  26. Behavioral Couples Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  27. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial

  28. Benznidazole

    BRIGHT MINDS BIOSCIENCES INC.

    Trypanosoma Cruzi Infection

    phase 2 small molecule completed

    1 trial

  29. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Colorectal Neoplasms

    phase 2 small molecule terminated

    1 trial

  30. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  31. Blinded study medication

    BRIGHT MINDS BIOSCIENCES INC.

    Knee Osteoarthritis

    phase 2 small molecule completed

    1 trial

  32. Brief computer-delivered intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  33. Brief motivational intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use

    phase 2 other completed

    1 trial

  34. Brief motivational intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse Detection

    phase 2 other completed

    1 trial

  35. Brincidofovir

    BRIGHT MINDS BIOSCIENCES INC.

    Ebola Virus Disease

    phase 2 small molecule terminated

    1 trial

  36. BufferGel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  37. Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 2 small molecule completed

    1 trial

  38. Buprenorphine Naloxone

    BRIGHT MINDS BIOSCIENCES INC.

    Maternal Opioid Use Disorder

    phase 2 small molecule completed

    1 trial

  39. Buprenorphine SL

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  40. Buprenorphine and Outpatient Parenteral Antibiotic Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 2 small molecule completed

    1 trial

  41. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 small molecule completed

    1 trial

  42. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia and Disorders With Psychotic Features

    phase 2 small molecule completed

    1 trial

  43. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    1 trial

  44. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine

    phase 2 small molecule completed

    1 trial

  45. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  46. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  47. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Amphetamine-Related Disorders

    phase 2 small molecule active

    2 trials

  48. Bupropion SR 150mg tabs

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Methamphetamine Abuse

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.